NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Juvenescence

Juvenescence

Private
DublinHealthcare & Life Scienceshttps://juvlabs.com/

Last Round

Series B

Extension

May 21, 2025

Est. Valuation

$500M

Total Funding Raised

$163M

Company Overview

Juvenescence is a biotechnology company that develops medicines and therapies designed to extend healthy human lifespan by targeting the core mechanisms of aging.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, D2C Brands, Sports & Fitness

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Data as a Service

AI Layer

Application

Keywords

longevitybiotech venture builderdrug discoveryregenerative medicinelongevity scienceAI drug discoverymetabolic healthbiohackingclinical stage therapeuticsbiotech startup studiolife sciences investmenttherapeutic pipelinehealthspangenerative chemistrybiomedical knowledge graph

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Juvenescence Comparables

Compare Juvenescence with similar companies based on industry and business-model similarity.

Juvenescence comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cambrian Bio
87%
BioAge Labs
78%
Altos Labs
77%

Juvenescence Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionMay 21, 2025
Series BAug 19, 2019
Series AJun 11, 2018
SeedJan 8, 2018

Key People

Founding team and executive leadership

Richard Marshall

Chief Executive Officer

Executive Team

David Gill

CFO

Executive Team

Gerson Montenegro

Chief Operating Officer - COO

Executive Team

Juvenescence Investors

Notable investors and investment history

Juvenescence investors
InvestorRounds
Grok VenturesSeries B
IPGLSeries B
SEED Innovations LimitedSeries A
Apeiron Investment GroupSeed
Foresite CapitalSeed
Oryx VenturesSeries B
SEED InnovationsSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 30, 2025

    Attended the Middle East Investors Summit in Abu Dhabi.

  • Jun 5, 2025

    Acquired Ro5 Inc. for $76 million.

Juvenescence Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Juvenescence Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Juvenescence's valuation, stock price, and market status.

Firmographic Details

HeadquartersDublin
Employee Range41
Year Founded2017
Last FundingMay 21, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.